Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility

Richard Lawson, Frederic King, Kevin Marsh, Arman Altincatal, Ali Cimen, Richard Lawson, Frederic King, Kevin Marsh, Arman Altincatal, Ali Cimen

Abstract

Introduction: Opioid-induced constipation (OIC) is the most common side effect of opioid treatment. Treatment for OIC typically involves a laxative. However, some patients have an inadequate response to these (laxative inadequate responders, or LIR). This has led to the development of treatments such as naloxegol. This analysis estimates the impact of naloxegol on the health state utility of LIR patients, examines if this utility impact is driven by the change in OIC status, and estimates the utility impact of relief of OIC.

Methods: The analysis was conducted using data from two 12-week randomized controlled trials, KODIAC 4 (ClinicalTrials.gov identifier, NCT01309841) and KODIAC 5 (ClinicalTrials.gov identifier, NCT01323790), plus KODIAC 7 (ClinicalTrials.gov identifier, NCT01395524), a 12-week extension to KODIAC 4. All were designed to assess the efficacy and safety of oral naloxegol (12.5 and 25 mg) compared to placebo. Health state utility data were collected through the EuroQol-five dimensions questionnaire (EQ-5D-3L). Descriptive analysis was undertaken to estimate how EQ-5D utility scores and EQ-5D domain responses varied with treatment, OIC status, and over time. A repeated measure mixed-effects model was used to predict the change from baseline in health state utility score over time.

Results: Compared with placebo, LIR patients treated with naloxegol 25 mg reported a 0.08 improvement in the EQ-5D overall score after 12 weeks of treatment. The analyses also suggest that change in OIC status is a key driver of the impact of OIC treatment on health state utility. When other factors are controlled, relieving OIC is associated with a 0.05 improvement in health state utility, although treatment with naloxegol is associated with an improvement in health state utility over and above the improvement in OIC status.

Conclusion: These analyses suggest that treatment with naloxegol improves patients' health state utility; driven predominantly by the relief of patients' constipation.

Funding: AstraZeneca.

Keywords: Constipation; EQ-5D; Gastroenterology; Health related quality of life; Laxative inadequate responder (LIR); Naloxegol; OIC; Opioid-induced constipation; Pain; Utility.

Figures

Fig. 1
Fig. 1
Change in percent of patients in EQ-5D domains, baseline to week 12 (KODIAC 4 and 5)

References

    1. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181–1187. doi: 10.1111/j.1742-1241.2007.01415.x.
    1. Coyne KS, LoCasale RJ, Datto CJ, Sexton CC, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269–281. doi: 10.2147/CEOR.S61602.
    1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333. doi: 10.1016/j.ejpain.2005.06.009.
    1. Reid KJ, Harker J, Bala MM, Truyers C, Kellen E, Bekkering GE, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin. 2011;27:449–462. doi: 10.1185/03007995.2010.545813.
    1. Sng BL, Schug SA. The role of opioids in managing chronic non-cancer pain. Ann Acad Med Singapore. 2009;38:960–966.
    1. Ueberall MA, Mueller-Schwefe GH. Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids. J Pain Res. 2015;8:459–475. doi: 10.2147/JPR.S88076.
    1. Annunziata K FD, Janning S, Williams R, Bell T. Constipation is a predominant side effect of opioid treatment for persistent pain. In: American Pain Society, 25th Annual Meeting, San Antonio, Texas; 2006.
    1. Langley PC. The prevalence, correlates and treatment of pain in the European Union. Curr Med Res Opin. 2011;27:463–480. doi: 10.1185/03007995.2010.542136.
    1. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain. 2010;11:1230–1239. doi: 10.1016/j.jpain.2010.07.002.
    1. Toblin RL, Mack KA, Perveen G, Paulozzi LJ. A population-based survey of chronic pain and its treatment with prescription drugs. Pain. 2011;152:1249–1255. doi: 10.1016/j.pain.2010.12.036.
    1. Boulanger A, Clark AJ, Squire P, Cui E, Horbay GL. Chronic pain in Canada: have we improved our management of chronic noncancer pain? Pain Res Manag. 2007;12:39–47. doi: 10.1155/2007/762180.
    1. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada–prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag. 2002;7:179–184. doi: 10.1155/2002/323085.
    1. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer. 1998;6:356–364. doi: 10.1007/s005200050177.
    1. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1) Pain Med. 2009;10:35–42. doi: 10.1111/j.1526-4637.2008.00495.x.
    1. Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage. 2010;40:696–703. doi: 10.1016/j.jpainsymman.2010.02.019.
    1. Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A, et al. A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med. 2013;27:447–456. doi: 10.1177/0269216312450358.
    1. Goodheart CR, Leavitt SB. Managing Opioid-Induced Constipation in Ambulatory-Care Patients. . Pain Treatment Topics 2006; August: 1–9. Accessed Dec 2014.
    1. Epstein RS, Cimen A, Benenson H, Aubert RE, Khalid M, Sostek MB, et al. Patient preferences for change in symptoms associated with opioid-induced constipation. Adv Ther. 2014;31:1263–1271. doi: 10.1007/s12325-014-0169-x.
    1. Müller-Lissner S. Opioid-induced constipation—mechanisms, relevance and management. . Eur Gastroenterol Hepatol Rev 2010; 6: 54–7. Accessed Jan 2015.
    1. Annemans L. Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. Clin Drug Investig. 2011;31:73–86. doi: 10.1007/BF03256935.
    1. McMillan SC. Presence and severity of constipation in hospice patients with advanced cancer. Am J Hosp Palliat Care. 2002;19:426–430. doi: 10.1177/104990910201900616.
    1. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106:835–842. doi: 10.1038/ajg.2011.30.
    1. Gupta S, Patel H, Sarangpur S, Mody R. Impact of opioid-induced constipation on opioid therapy management among chronic opioid users based on a patient survey (abstract) American Pain Society. 2014;15(4):S6. doi: 10.1016/j.jpain.2014.01.026.
    1. Holzer P. New approaches to the treatment of opioid-induced constipation. Eur Rev Med Pharmacol Sci. 2008;12(Suppl 1):119–127.
    1. National Institute for Health and Care Excellence (NICE). Process and methods guides: Guide to the methods of technology appraisal 2013. London: NICE; 2013. . Accessed May 2014.
    1. Penning-van Beest FJ, van den Haak P, Klok RM, Prevoo YF, van der Peet DL, Herings RM. Quality of life in relation to constipation among opioid users. J Med Econ. 2010;13:129–135. doi: 10.3111/13696990903584436.
    1. Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31:800–804. doi: 10.1177/0272989X11401031.
    1. Bennett L, Zhao Z, Barber B, Zhou X, Peeters M, Zhang J, et al. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer. 2011;105:1495–1502. doi: 10.1038/bjc.2011.409.
    1. Farkkila N, Torvinen S, Roine RP, Sintonen H, Hanninen J, Taari K, et al. Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease. Qual Life Res. 2014;23:1387–1394. doi: 10.1007/s11136-013-0562-y.
    1. Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1) J Thorac Oncol. 2013;8:229–237. doi: 10.1097/JTO.0b013e3182773fce.
    1. Luengo-Fernandez R, Gray AM, Bull L, Welch S, Cuthbertson F, Rothwell PM, et al. Quality of life after TIA and stroke: ten-year results of the Oxford vascular study. Neurology. 2013;81:1588–1595. doi: 10.1212/WNL.0b013e3182a9f45f.
    1. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13:873–884. doi: 10.1002/hec.866.
    1. Thomas KJ, MacPherson H, Ratcliffe J, Thorpe L, Brazier J, Campbell M, et al. Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain. Health Technol Assess. 2005;9:iii–iv, ix–x, 1–109.
    1. Ahmedzai SH, Leppert W, Janecki M, Pakosz A, Lomax M, Duerr H, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015;23:823–830. doi: 10.1007/s00520-014-2435-5.
    1. Guijarro P, Alonso-Babarro A, Viqueira A, Fernandez G. Economic burden of opioid induced constipation in Spain. Value Health. 2010;13:A369. doi: 10.1016/S1098-3015(11)72490-1.
    1. Brock C, Olesen SS, Olesen AE, Frokjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72:1847–1865. doi: 10.2165/11634970-000000000-00000.
    1. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387–2396. doi: 10.1056/NEJMoa1310246.
    1. Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United Eur Gastroenterol J. 2015;3:471–480. doi: 10.1177/2050640615604543.
    1. EuroQoL Group. EQ-5D FAQs. Rotterdam: EuroQol Research Foundation; 2014. . Accessed May 2014.
    1. World Health Organization (WHO). WHO’s cancer pain ladder for adults. 2016. . Accessed Oct 2014.
    1. Morlion B, Clemens KE, Dunlop W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. Clin Drug Investig. 2015;35:1–11. doi: 10.1007/s40261-014-0254-6.
    1. Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014;14:221–233. doi: 10.1586/14737167.2014.894462.
    1. World Health Organization (WHO). WHO methods and data sources for global burden of disease estimates 2000-2011. 2013. . Accessed Feb 2016.
    1. Rome Foundation. Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. Raleigh, NC: Rome Foundation; 2006. . Accessed Sept 2014.
    1. Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ. 1999;8:41–51. doi: 10.1002/(SICI)1099-1050(199902)8:1<41::AID-HEC395>;2-#.
    1. Aspinall PA, Johnson ZK, Azuara-Blanco A, Montarzino A, Brice R, Vickers A. Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol Vis Sci. 2008;49:1907–1915. doi: 10.1167/iovs.07-0559.
    1. Bozzani FM, Alavi Y, Jofre-Bonet M, Kuper H. A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. BMC Ophthalmol. 2012;12:43. doi: 10.1186/1471-2415-12-43.
    1. Chisholm D, Healey A, Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol. 1997;32:68–75. doi: 10.1007/BF00788923.
    1. Donaldson C, Atkinson A, Bond J, Wright K. Should QALYs be programme-specific? J Health Econ. 1988;7:239–257. doi: 10.1016/0167-6296(88)90027-6.
    1. Kobelt G, Jonsson B, Bergstrom A, Chen E, Linden C, Alm A. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand. 2006;84:363–371. doi: 10.1111/j.1600-0420.2005.00621.x.
    1. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol. 2005;40:540–551. doi: 10.1080/00365520510012208.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir